Selected article for: "antibody assay and live virus"
Author: Temperton, Nigel J.; Chan, Paul K.; Simmons, Graham; Zambon, Maria C.; Tedder, Richard S.; Takeuchi, Yasuhiro; Weiss, Robin A.
Title: Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes
  • Cord-id: gvnylnen
  • Document date: 2005_3_25
    • ID: gvnylnen
    Snippet: The severe acute respiratory syndrome–associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay that is both sensitive and specific for SARS-CoV neutralizing antibodies. Neutralization titers measured by this assay are highly correlated to those measured by an assay using replication-competent SARS-CoV. No cross-neutralization occurred with
    Document: The severe acute respiratory syndrome–associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay that is both sensitive and specific for SARS-CoV neutralizing antibodies. Neutralization titers measured by this assay are highly correlated to those measured by an assay using replication-competent SARS-CoV. No cross-neutralization occurred with human sera known to contain antibodies to coronavirus strains OC43 and 229E. The pseudotype assay was used to profile neutralizing antibody responses against SARS-CoV S in sequential serum samples taken from 41 confirmed SARS patients during the 2003 outbreak in Hong Kong and shows long-lasting immunity in most recovered patients. The pseudotype assay does not require handling live SARS virus; it is a useful tool to determine neutralizing titers during natural infection and the preclinical evaluation of candidate vaccines.

    Search related documents:
    Co phrase search for related documents
    • accurate determination and live virus: 1, 2
    • acute phase and live virus: 1, 2, 3, 4, 5, 6
    • acute phase and longevity magnitude: 1
    • acute respiratory syndrome and adenoviral vaccine: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute respiratory syndrome and live virus assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory syndrome and live virus challenge: 1
    • acute respiratory syndrome and live virus neutralization: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and longevity magnitude: 1
    • acute respiratory syndrome and longitudinal profile: 1, 2, 3, 4
    • adenoviral vaccine and live virus: 1, 2
    • adenoviral vaccine and live virus assay: 1
    • live virus and longevity magnitude: 1